News
Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...
2d
Zacks Investment Research on MSNMRNA Stock Jumps on CDC's Revised RSV Vaccine RecommendationsShares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...
We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.
The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.
Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...
The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...
In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...
Records show that a top U.S. regulator rejected the recommendations of agency experts and limited the use of Covid vaccines.
Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...
Professor Hirohide Saito (Department of Life Science Frontiers at CiRA / The University of Tokyo) and Assistant Professor ...
Two young elephants at the Zoo, Sanjay and Kabir, overcame a deadly virus thanks to a new vaccine introduced to zoos ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results